EC approves PADCEV and KEYTRUDA combo for advanced urothelial cancer treatment

Pallavi Madhiraju- August 28, 2024

Astellas Pharma Inc. has announced a significant milestone in cancer treatment with the European Commission (EC's) approval of PADCEV (enfortumab vedotin) combined with KEYTRUDA (pembrolizumab). ... Read More

Health Canada approves KEYTRUDA and Enfortumab Vedotin for advanced urothelial cancer

Pallavi Madhiraju- August 22, 2024

Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced that Health Canada has granted approval for KEYTRUDA (pembrolizumab) in combination ... Read More

Breakthrough in cancer treatment: China approves PADCEV for advanced urothelial cancer

Pallavi Madhiraju- August 20, 2024

China's National Medical Products Administration (NMPA) has granted approval for PADCEV (enfortumab vedotin) to treat locally advanced or metastatic urothelial cancer (la/mUC) in adult patients. ... Read More

Japan’s MHLW grants priority review for PADCEV and KEYTRUDA combo in urothelial cancer

Pallavi Madhiraju- February 18, 2024

In a significant development in the fight against urothelial cancer, Astellas Pharma Inc. announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has awarded ... Read More

Advancing bladder cancer treatment: EMA scrutinizes Astellas-Pfizer’s innovative therapy

Pallavi Madhiraju- January 28, 2024

A groundbreaking development in bladder cancer treatment is on the horizon as Astellas Pharma Inc. and Pfizer Inc. await the European Medicines Agency’s (EMA) review ... Read More

Phase 3 EV-302 clinical trial : Seagen, Astellas reveal promising for PADCEV and KEYTRUDA combo

Pallavi Madhiraju- October 22, 2023

Seagen Inc. and Astellas Pharma Inc. have announced encouraging results from the Phase 3 EV-302 clinical trial, presenting PADCEV in combination with KEYTRUDA versus chemotherapy. ... Read More

PADCEV, KEYTRUDA combination for advanced bladder cancer gets FDA breakthrough therapy status

pharmanewsdaily- February 20, 2020

PADCEV, KEYTRUDA combination : Astellas Pharma and Seattle Genetics said that the combination of PADCEV (enfortumab vedotin-ejfv) and Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) has been ... Read More

Genetron Health’s semiconductor-based NGS system gets Chinese approval

pharmanewsdaily- December 30, 2019

Genetron Health has been granted approval by China’s National Medical Products Administration (NMPA) for GENETRON S5, its semiconductor-based next-generation sequencing system (NGS system). With the ... Read More

Astellas, Seattle Genetics bag Padcev FDA approval for advanced urothelial cancer

pharmanewsdaily- December 19, 2019

Padcev FDA approval : Astellas Pharma and Seattle Genetics have bagged accelerated approval from the US Food and Drug Administration (FDA) for Padcev (enfortumab vedotin-ejfv) ... Read More